Promising drug targets and associated therapeutic interventions in Parkinson’s disease
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is one of the most debilitating brain diseases. Despite the availability of symptomatic treatments, response towards the health of PD patients remains scarce. To fulfil the medical needs of the PD patients, an efficacious and etiological treatment is required. In this review, we have compiled the information covering limitations of current therapeutic options in PD, novel drug targets for PD, and finally, the role of some critical beneficial natural products to control the progression of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648 · cited 1×
“The nicotinamide adenine dinucleotide is derived from niacin which potentially affects the sleep-wake cycle through circadian rhythm and ultimately responsible for the oxidative pathways in mitochondria (Cantó et al., 2015; Yang and Sauve, 2016; Pehar et al., 2018).”
BackgroundThe synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 1×
“However, studies reported that SV2A might be a specific pharmacological target for the antiepileptic levetiracetam (Lynch et al., 2004; Löscher et al., 2016; Bartholome et al., 2017).”
Background-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446 · cited 1×
“Dopaminergic neurodegeneration and intracellular accumulation of insoluble α-Syn protein (encoded by the SNCA gene) as Lewy bodies and Lewy neurit is are the major pathological hal lmarks of PD progression (Stefanis, 2012).”
BackgroundMitophagy: mechanisms, pathophysiological roles, and analysis
Ding, W.-X., & Yin, X.-M. (2012) · bchm · doi:10.1515/hsz-2012-0119 · Cited by 1,032
Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies
Ciechanover, A., & Kwon, Y. T. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.117 · Cited by 898
Lee, H.-J., Suk, J.-E., Patrick, C., Bae, E.-J., Cho, J.-H., Rho, S., Hwang, D., Masliah, E., & Lee, S.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081125 · Cited by 877 · cited 1×
“The α-Syn aggregation has been reported to extend across the cell types and cell populations in brain (Lee et al., 2010; Brück et al., 2016).”
Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265
Molecular chaperones and proteostasis regulation during redox imbalance
Niforou, K., Cheimonidou, C., & Trougakos, I. P. (2014) · Redox Biology · doi:10.1016/j.redox.2014.01.017 · Cited by 250
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244
Cheng, J., Liao, Y., Dong, Y., Hu, H., Yang, N., Kong, X., Li, S., Li, X., Guo, J., Qin, L., et al. (2020) · Autophagy · doi:10.1080/15548627.2020.1719723 · Cited by 233 · cited 1×
“In the mouse model of PD, disease symptoms appear after inflammasome activation as a result of autophagic impairment mediated by microglial cells (Cheng et al., 2020).”
Background
Cited by
Jiang, Z., Wang, X., Zhang, H., Yin, J., Zhao, P., Yin, Q., & Wang, Z. (2023) · MedComm · doi:10.1002/mco2.268 · Cited by 50
Chen, G., Ahn, E. H., Kang, S. S., Xia, Y., Liu, X., Zhang, Z., & Ye, K. (2022) · Advanced Science · doi:10.1002/advs.202103396 · Cited by 28
Cao, X., Du, Z.-R., Liu, X., Wang, X., Li, C., Zhou, S.-N., Liu, J.-R., Xu, P.-Y., Ye, J.-L., Zhao, Q., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115100 · Cited by 15
“With regard to the underlying mechanisms, neuroinflammation, oxidative stress, and impaired autophagy have been implicated in the pathogenesis of PD [20 – 22].”
Metadata
- Authors
- Singh, M., Singh, B., Rai, S., Singh, P., Varshney, R., Chaturvedi, V., & Vamanu, E.
- Venue
- Neural Regeneration Research
- Publisher
- Medknow
- Published
- 2021
- Volume
- 16
- Issue
- 9
- Pages
- 1730
- ISSN
- 1673-5374 (ISSN-L)
- OpenAlex
- W3122457631
- Cited by
- 108
- References
- 16
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Promising drug targets and associated therapeutic interventions in Parkinson’s disease. https://app.cochat.ai/papers/10.4103/1673-5374.306066
- The paper
- Singh, M., Singh, B., Rai, S., Singh, P., Varshney, R., Chaturvedi, V., & Vamanu, E. (2021). Promising drug targets and associated therapeutic interventions in Parkinson’s disease. Neural Regeneration Research. https://doi.org/10.4103/1673-5374.306066
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.